Silva Arslanian-Makaroun
Pittsburgh, PANPI 1649242033
Payments from drug & device makers
$1,365,916in general payments, 2019–2025
Across 5,098 payments — averaging $267.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$1.1M
- Eli Lilly$223K
- Novo Nordisk$13K
- Astrazeneca UK Limited$12K
- Sanofi-aventis U.S. LLC$8K
- Boehringer Ingelheim International GmbH$7K
- plus $1K from 7 others
$24,235in research payments, 2019–2025
Across 10 payments — averaging $2423.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$19K
- Astrazeneca UK Limited$4K
- Eli Lilly$664
General payments by program year
19
20
21
22
23
24
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 5,036 | $1,101,867 |
| Eli Lilly | 26 | $223,451 |
| Novo Nordisk | 15 | $12,541 |
| Astrazeneca UK Limited | 5 | $11,573 |
| Sanofi-aventis U.S. LLC | 2 | $8,242 |
| Boehringer Ingelheim International GmbH | 6 | $6,901 |
| Rhythm Pharmaceuticals, Inc. | 1 | $675 |
| W. L. Gore & Associates, Inc. | 2 | $309 |
| Amgen | 1 | $150 |
| Abbott | 1 | $124 |
| AstraZeneca | 1 | $36 |
| Medtronic | 1 | $26 |
| Chiesi USA, Inc. | 1 | $21 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.